About us Newsletter News Widget Media Inquiries

Media Inquiries

Your experience will be better in the app

Install

Sign Up | Log In

Menu

Contact Us Terms of Service Support Privacy Policy Archive

© 2024 Otherweb

Subscribe to our newsletter

Everything you need to know about today's news — in your inbox each morning.

It’s free

By continuing, you agree to Otherweb's Terms of Service and acknowledge you've read our Privacy Policy

Follow

Featured Podcast EpisodesThe Other Web

Alex Fink

Zuckerman vs Zuckerberg

July 14, 2024

Ethan Zuckerman is a professor at the University of Massachusetts Amherst and a scholar of digital media. He and his team work to understand the contemporary digital world and build social media systems that are focused on communities, not on profits. Ethan is currently suing Meta (i.e. Facebook) in a landmark case that might (and likely should) change our interpretation of section 230. Please tune in to hear the details of the case and the various ways it could change the social media landscape. It's fascinating!

Prof. Jeff Jarvis - Rewriting Media's Business Model (Yet Again)

May 24, 2024

Jeff Jarvis is a journalism professor at the City College in New York (CUNY), the author of six books, and the cohost of the successful podcast "This week in Google and AI". Jeff spent many years teaching entrepreneurial journalism - and God knows journalism could use some entrepreneurial spirit, right about now. Please check out Jeff's books, The Gutenberg Parenthesis and Magazine, both from Bloomsbury (discount codes here: gutenbergparenthesis.com).

Donald Robertson - Where Philosophy Meets Psychology

June 22, 2024

Our guest today is Donald Robertson - Donald is a cognitive-behavioral psychotherapist and author of several books, including How to Think Like a Roman Emperor and, more recently, Marcus Aurelius: The Stoic Emperor. He is one of the founders of the Modern Stoicism nonprofit organization and the founder and president of the Plato's Academy Centre in Athens, Greece. He was born in Scotland but now lives in Montreal, Canada. His upcoming book, How to Think Like Socrates, will be released later this year, and can be preordered on Amazon, Barnes and Noble, or anywhere else books are generally sold.

Rick Edmonds - Analyzing the Financial Decline of Legacy Media

July 8, 2024

Rick Edmonds is the media business analyst for the Poynter Institute, a school and study center for working journalists. He has been doing research and writing for 25 years on the financial decline of legacy media, newspapers particularly, and the rise of new media alternatives. His reporting and commentary appear regularly on the Poynter Online site. He has spoken to conference groups in the U.S.A. and in Paris, Norway, Madrid, Vienna and Chile.

Jonathan Green - How To Make ChatGPT and Other Tools Useful (Right Now)

July 5, 2024

Welcome to the Otherweb. Our guest today is Jonathan Green - a bestselling author of hundreds of books, a celebrity ghostwriter, and an expert in using artificial intelligence tools to their utmost capacity. This is the best conversation I've had on the practical implications of ChatGPT and how regular people can augment their own capabilities by using these tools as a shortcut.

1h 4m

News from Zepbound

Stay current with all the latest and breaking news about Zepbound, compare headlines and perspectives between news sources on stories happening today. In total, 20 stories have been published about Zepbound which Ground News has aggregated in the past 3 months.

Recent news

Yahoo Finance

Yahoo Finance

The weight-loss frenzy is making some pharma stocks much more volatile. Will the drama continue?

View summary

The Motley Fool

The Motley Fool

Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip

View summary

USA Today

USA Today

Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound

USA Today

View summary

Latest news stories

GuruFocus | Stock Market Research, Data and Tools

GuruFocus | Stock Market Research, Data and Tools

Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market

GuruFocus | Stock Market Research, Data and Tools

View summary

Wired

Wired

The Crackdown on Compounded GLP-1 Meds Has Begun

Wired

View summary

Wired

Wired

A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating

Wired

View summary

Reuters

Reuters

US FDA says Lilly's weight-loss drug no longer in shortage

Reuters

View summary

Yahoo

Yahoo

Weight loss drugs like Ozempic are all over the news. Here's what I'm reading to keep up as a health reporter.

Yahoo

View summary

CNBC

CNBC

Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock

CNBC

View summary

ScienceAlert

ScienceAlert

Weight Loss Drug Reduces Diabetes Risk by 94 Percent in Clinical Trial

ScienceAlert

View summary

Yahoo

Yahoo

A cheaper weight loss drug, more heat-related deaths and new restrictions on tobacco sales: Here's what happened in health this week

Yahoo

View summary

Ars Technica

Ars Technica

Eli Lilly raises price of Zepbound while trumpeting discount on starter vials

Ars Technica

View summary

CNBC

CNBC

Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply

CNBC

View summary

CNBC

CNBC

Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial

CNBC

View summary

Verywell Health

Verywell Health

Can You Take Mounjaro for Weight Loss?

Verywell Health

View summary

Reuters

Reuters

Eli Lilly raises annual forecasts as weight-loss drug quarterly sales cross $1 billion

Reuters

View summary

CNBC

CNBC

Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

CNBC

View summary

NBC News

NBC News

Weight loss drugs like Wegovy may trigger eating disorders in some patients, doctors warn

NBC News

View summary

Reuters

Reuters

Lilly, Novo Nordisk battle for weight-loss market lands at the pharmacy shelf

Reuters

View summary

Reuters

Reuters

Lilly says weight loss drug cut heart failure risk by 38% in trial

Reuters

View summary